Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study

Article de revue

Avec comité de lecture

Michael Wechsler, Linda Rogers, Giorgio Canonica, Arnaud Bourdin, Arman Altincatal, Megan Hardin, Xavier Soler, Paul Rowe, Yamo Deniz, Harry Sacks, …

Journal of allergy and clinical immunology, Vol.153(2), p.AB96

02/2024

Indicateurs

1 Consultations de la notice

Titre: Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study
Créateurs - sans rôle: Michael Wechsler
Linda Rogers
Giorgio Canonica
Arnaud Bourdin
Arman Altincatal
Megan Hardin
Xavier Soler
Paul Rowe
Yamo Deniz
Harry Sacks
Juby Jacob-Nara
Détails de publication: Journal of allergy and clinical immunology, Vol.153(2), p.AB96
Identifiants: 99158804109311
Unité académique: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Langue: English
Type de ressource: Journal article